Top-News

Capricor Therapeutics Aktie News

Aktie
WKN:  A2PLU4 ISIN:  US14070B3096 US-Symbol:  CAPR Branche:  Biotechnologie Land:  USA
26,70 $
+1,30 $
+5,12%
22,936 € 21:10:47 Uhr
Depot/Watchlist
Marktkapitalisierung *
157,36 Mio. €
Streubesitz
52,59%
KGV
-12
Index-Zuordnung
-

Capricor Therapeutics News

03.08.25 - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
01.08.25 - PR Newswire
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for Investors - Contact Levi & Korsinsky
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for Investors - Contact Levi & Korsinsky PR Newswire
31.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR PR Newswire
31.07.25 - PR Newswire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR PR Newswire
30.07.25 - PR Newswire
Robbins LLP Reminds CAPR Investors with Large Losses of the Class Action Lawsuit on Behalf of Capricor Therapeutics, Inc. Shareholders
Robbins LLP Reminds CAPR Investors with Large Losses of the Class Action Lawsuit on Behalf of Capricor Therapeutics, Inc. Shareholders PR Newswire
29.07.25 - PR Newswire
Shareholders that lost money on Capricor Therapeutics should contact Faruqi & Faruqi about pending Class Action - CAPR
Shareholders that lost money on Capricor Therapeutics should contact Faruqi & Faruqi about pending Class Action - CAPR PR Newswire
29.07.25 - PR Newswire
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR
Capricor Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before September 15, 2025 to Discuss Your Rights - CAPR PR Newswire
28.07.25 - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
28.07.25 - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
28.07.25 - PR Newswire
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against Capricor Therapeutics, Inc. (CAPR) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire
27.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR PR Newswire
25.07.25 - PR Newswire
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR PR Newswire
25.07.25 - PR Newswire
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR PR Newswire
24.07.25 - PR Newswire
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Shareholders that lost money on Capricor Therapeutics, Inc.(CAPR) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire
23.07.25 - PR Newswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics PR Newswire
22.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR PR Newswire
22.07.25 - PR Newswire
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
Capricor Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - ...
21.07.25 - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit PR Newswire
21.07.25 - PR Newswire
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
CAPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action ...
21.07.25 - PR Newswire
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +1,03%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »